May 05, 2014 19:08 ET
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 5, 2014) - Supreme Pharmaceuticals Inc. (the "Company") (CSE:SL)(OTCBB:SPRWF) has granted 12,000,000 incentive stock options to directors, officers and consultants at an exercise price of $0.05 for a term of five years from this day May 5th, 2014.
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the issuance of the MMPR license. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to exercise the option, acquire any producing facility and the facility's inability to acquire a MMPR license. This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.
Zach Stadnyk, Investor Relations(647) firstname.lastname@example.org
See all RSS Newsfeeds